Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
← catalyst calendarNCT06126380 · readout ≤ 1,230 d
Sponsored by Eledon Pharmaceuticals (industry) · ELDN — their whole pipeline →.
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
132estimated
Sites
43
Countries
Australia, Brazil, Canada +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-25 | actual | When the study began enrolling |
| Primary completion | Dec 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Kidney Transplant Rejection
Interventions
- Drug: AT-1501 — also filed as Tegoprubart
- Drug: Tacrolimus
Primary outcomes
what the primary-completion date above is the date OFSafety and Tolerability - Incidence of Treatment Emergent Adverse Events
measured Assessed from date of enrollment through Month 48
Safety and Tolerability - Kidney Transplant Medication Side Effects
measured Assessed from date of enrollment through Month 48
Permalink · ELDN's whole pipeline · Catalyst calendar · Every registered study · What changed